TD Asset Management Inc. Sells 339,161 Shares of Hologic, Inc. (NASDAQ:HOLX)

TD Asset Management Inc. trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,555,985 shares of the medical equipment provider's stock after selling 339,161 shares during the period. TD Asset Management Inc. owned 0.69% of Hologic worth $112,171,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in HOLX. First Horizon Advisors Inc. raised its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. Brooklyn Investment Group grew its position in Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after acquiring an additional 145 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 169 shares during the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of Hologic by 29.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider's stock valued at $66,000 after purchasing an additional 183 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

HOLX has been the subject of several research reports. Evercore ISI dropped their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Morgan Stanley cut their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Citigroup dropped their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Stephens restated an "overweight" rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Finally, Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Trading Down 1.6 %

Shares of Hologic stock traded down $1.00 on Friday, reaching $61.32. 1,110,999 shares of the company's stock were exchanged, compared to its average volume of 1,809,690. The company has a market capitalization of $13.76 billion, a P/E ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm's 50-day moving average is $65.24 and its two-hundred day moving average is $73.29.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.